Base de dados : MEDLINE
Pesquisa : N01.824.417.700.325 [Categoria DeCS]
Referências encontradas : 9468 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 947 ir para página                         

  1 / 9468 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29359891
[Au] Autor:Office of Personnel Management.
[Ti] Título:Federal Employees Health Benefits Program: Removal of Eligible and Ineligible Individuals From Existing Enrollments. Final rule.
[So] Source:Fed Regist;83(15):3059-62, 2018 Jan 23.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The United States Office of Personnel Management (OPM) is issuing a final rule amending Federal Employees Health Benefits (FEHB) Program regulations to provide a process for removal of certain identified individuals who are found not to be eligible as family members from FEHB enrollments. This process would apply to individuals for whom there is a failure to provide adequate documentation of eligibility when requested. This action also amends Federal Employees Health Benefits (FEHB) Program regulations to allow certain eligible family members to be removed from existing self and family or self plus one enrollments.
[Mh] Termos MeSH primário: Empregados do Governo/legislação & jurisprudência
Planos de Assistência de Saúde para Empregados/legislação & jurisprudência
[Mh] Termos MeSH secundário: Definição da Elegibilidade/legislação & jurisprudência
Família
Seres Humanos
Cobertura do Seguro/legislação & jurisprudência
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  2 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29319943
[Au] Autor:Office of the Secretary, Department of Defense (DoD).
[Ti] Título:TRICARE; Reimbursement of Long Term Care Hospitals and Inpatient Rehabilitation Facilities. Final rule.
[So] Source:Fed Regist;82(249):61678-94, 2017 Dec 29.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This final rule establishes reimbursement rates for Long Term Care Hospitals (LTCHs) and Inpatient Rehabilitation Facilities (IRFs) in accordance with the statutory requirement that TRICARE inpatient care "payments shall be determined to the extent practicable in accordance with the same reimbursement rules as apply to payments to providers of services of the same type under Medicare." This final rule adopts Medicare's reimbursement methodologies for inpatient services provided by LTCHs and IRFs. Each reimbursement methodology will be phased in over a 3-year period. This final rule also removes the definitions for "hospital, long-term (tuberculosis, chronic care, or rehabilitation)" and "long-term hospital care," and creates separate definitions for "Long Term Care Hospital" and "Inpatient Rehabilitation Facility" adopting Centers for Medicare & Medicaid Services (CMS) classification criteria. This final rule also includes authority for a year-end, discretionary General Temporary Military Contingency Payment Adjustment (GTMCPA) for inpatient services in TRICARE network IRFs when deemed essential to meet military contingency requirements.
[Mh] Termos MeSH primário: Planos de Assistência de Saúde para Empregados/economia
Reembolso de Seguro de Saúde/economia
Assistência de Longa Duração/economia
Centros de Reabilitação/economia
Mecanismo de Reembolso/economia
Instituições de Cuidados Especializados de Enfermagem/economia
[Mh] Termos MeSH secundário: Economia Hospitalar
Seres Humanos
Militares
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180122
[Lr] Data última revisão:
180122
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE


  3 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29346342
[Au] Autor:Anderson KN; Ailes EC; Danielson M; Lind JN; Farr SL; Broussard CS; Tinker SC
[Ti] Título:Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15-44 Years - United States, 2003-2015.
[So] Source:MMWR Morb Mortal Wkly Rep;67(2):66-70, 2018 Jan 19.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects individuals across the lifespan. ADHD medication use among pregnant women is increasing (1), but consensus about the safety of ADHD medication use during pregnancy is lacking. Given that nearly half of U.S. pregnancies are unintended (2), and early pregnancy is a critical period for fetal development, examining trends in ADHD medication prescriptions among reproductive-aged women is important to quantify the population at risk for potential exposure. CDC used the Truven Health MarketScan Commercial Database* for the period 2003-2015 to estimate the percentage of women aged 15-44 years with private employer-sponsored insurance who filled prescriptions for ADHD medications each year. The percentage of reproductive-aged women who filled at least one ADHD medication prescription increased 344% from 2003 (0.9% of women) to 2015 (4.0% of women). In 2015, the most frequently filled medications were mixed amphetamine salts, lisdexamfetamine, and methylphenidate. Prescribing ADHD medications to reproductive-aged women is increasingly common; additional research on ADHD medication safety during pregnancy is warranted to inform women and their health care providers about any potential risks associated with ADHD medication exposure before and during pregnancy.
[Mh] Termos MeSH primário: Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Prescrições de Medicamentos/estatística & dados numéricos
Seguro Saúde/estatística & dados numéricos
Setor Privado/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Estimulantes do Sistema Nervoso Central/efeitos adversos
Estimulantes do Sistema Nervoso Central/uso terapêutico
Feminino
Planos de Assistência de Saúde para Empregados/estatística & dados numéricos
Seres Humanos
Formulário de Reclamação de Seguro
Gravidez
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180121
[Lr] Data última revisão:
180121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180119
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6702a3


  4 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29215239
[Au] Autor:Fronstin P; Roebuck MC
[Ti] Título:Health Plan Switching: A Case Study--Implications for Private- and Public-Health-Insurance Exchanges and Increased Health Plan Choice.
[So] Source:EBRI Issue Brief;(432):1-20, 2017 03 23.
[Is] ISSN:0887-137X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Comportamento de Escolha
Planos de Assistência de Saúde para Empregados/estatística & dados numéricos
Trocas de Seguro de Saúde
Seguro Saúde/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Sistemas Pré-Pagos de Saúde/estatística & dados numéricos
Seres Humanos
Seguradoras/estatística & dados numéricos
Masculino
Poupança para Cobertura de Despesas Médicas/estatística & dados numéricos
Meia-Idade
Organizações de Prestadores Preferenciais/estatística & dados numéricos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:H
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE


  5 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29215232
[Au] Autor:Hall MA; Fronstin P
[Ti] Título:Narrow Provider Networks for Employer Plans.
[So] Source:EBRI Issue Brief;(428):1-17, 2016 12 14.
[Is] ISSN:0887-137X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Planos de Assistência de Saúde para Empregados/economia
Seguro Saúde/economia
[Mh] Termos MeSH secundário: Adulto
Competição Econômica
Feminino
Trocas de Seguro de Saúde
Acesso aos Serviços de Saúde
Seres Humanos
Masculino
Patient Protection and Affordable Care Act
Pesquisa Qualitativa
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:H
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE


  6 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29239587
[Au] Autor:Roth LR
[Ad] Endereço:St. John's University School of Law.
[Ti] Título:Redefining "Medical Care."
[So] Source:Cornell J Law Public Policy;27(1):65-106, 2017.
[Is] ISSN:1069-0565
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:President Donald J. Trump has said he will repeal the Affordable Care Act (ACA) and replace it with health savings accounts (HSAs). Conservatives have long preferred individual accounts to meet social welfare needs instead of more traditional entitlement programs. The types of "medical care" that can be reimbursed through an HSA are listed in section 213(d) of the Internal Revenue Code (Code) and include expenses "for the diagnosis, cure, mitigation, treatment, or prevention of disease, or for the purpose of affecting any structure or function of the body." In spite of the broad language, regulations and court interpretations have narrowed this definition substantially. It does not include the many social factors that determine health outcomes. Though the United States spends over seventeen percent of gross domestic product (GDP) on "healthcare", the country's focus on the traditional medicalized model of health results in overall population health that is far beneath the results of other countries that spend significantly less. Precision medicine is one exceptional way in which American healthcare has focused more on individuals instead of providing broad, one-size-fits-all medical care. The precision medicine movement calls for using the genetic code of individuals to both predict future illness and to target treatments for current illnesses. Yet the definition of "medical care" under the Code remains the same for all. My proposal for precision healthcare accounts involves two steps-- the first of which requires permitting physicians to write prescriptions for a broader range of goods and services. The social determinants of health are as important to health outcomes as are surgical procedures and drugs--or perhaps more so according to many population health studies. The second step requires agencies and courts to interpret what constitutes "medical care" under the Code differently depending on the taxpayer's income level. Childhood sports programs and payments for fruits and vegetables may be covered for those in the lower income brackets who could not otherwise afford these items and would not choose to spend scarce resources on them if they could. This all assumes that the government takes funds previously used to subsidize the purchase of health insurance under the ACA (or allocates new funds) and puts the funds in individual accounts so the poor or near poor have money to pay for these expenses. Section I of this Article will explore the current definition of medical care, which excludes the social determinants of health from "healthcare" spending. I then address how precision medicine has changed the types of services and treatments that it makes sense to reimburse for each individual. If efficacy can vary from person to person based on genetic code, then it also can vary depending on environment. There is an opportunity to not only vary the types of "medical care" that can be reimbursed or deducted within the traditional range of services and drugs, but also outside of that range. Section II addresses the historical shift towards health financing through individual accounts, and specifically through HSAs. If this is the only avenue for health reform in the next few years, I advocate using it to engage in the type of experiments that are typically only possible under the cover of tax expenditures. My proposal for precision healthcare accounts moves the government to experiment with individual social spending that can lead to improved overall health outcomes. Finally, in Section III, I address two dichotomies that affect any healthcare proposal: (1) entitlement programs v. grants-in-aid, and (2) pooled insurance v. consumer-driven health plans (CDHPs). In the end, I argue that an entitlement method of funding precision HSAs along with pooled insurance subsidized by the government is the most realistic resolution to these dichotomies. Only a broad-based entitlement to funding for all healthcare expenses (medical and social) allows for significant improvements in overall population health.
[Mh] Termos MeSH primário: Assistência à Saúde/legislação & jurisprudência
Poupança para Cobertura de Despesas Médicas/legislação & jurisprudência
Determinantes Sociais da Saúde/legislação & jurisprudência
[Mh] Termos MeSH secundário: Dedutíveis e Cosseguros
Planos de Assistência de Saúde para Empregados
Seres Humanos
Cobertura do Seguro
Seguro Saúde
Patient Protection and Affordable Care Act
Medicina de Precisão
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  7 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28933347
[Au] Autor:Grosse SD; Waitzman NJ; Yang N; Abe K; Barfield WD
[Ad] Endereço:National Center on Birth Defects and Developmental Disabilities, sgrosse@cdc.gov.
[Ti] Título:Employer-Sponsored Plan Expenditures for Infants Born Preterm.
[So] Source:Pediatrics;140(4), 2017 Oct.
[Is] ISSN:1098-4275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Care for infants born preterm or with major birth defects is costly. Specific estimates of financial burden for different payers are lacking, in part because use of administrative data to identify preterm infants and costs is challenging. METHODS: We used private health insurance claims data and billing codes to identify live births during 2013 and calculated first-year expenditures for employer-sponsored health plans for infants born preterm, both overall and stratified by major birth defects. RESULTS: We conservatively estimated that 7.7% of insured infants born preterm accounted for 37% of $2.0 billion spent by participating plans on the care of infants born during 2013. With a mean difference in plan expenditures of ∼$47 100 per infant, preterm births cost the included plans an extra $600 million during the first year of life. Extrapolating to the national level, we projected aggregate employer-sponsored plan expenditures of $6 billion for infants born preterm during 2013. Infants with major birth defects accounted for 5.8% of preterm births but 24.5% of expenditures during infancy. By using an alternative algorithm to identify preterm infants, it was revealed that incremental expenditures were higher: $78 000 per preterm infant and $14 billion nationally. CONCLUSION: Preterm births (especially in conjunction with major birth defects) represent a substantial burden on payers, and efforts to mitigate this burden are needed. In addition, researchers need to conduct studies using linked vital records, birth defects surveillance, and administrative data to accurately and longitudinally assess per-infant costs attributable to preterm birth and the interaction of preterm birth with major birth defects.
[Mh] Termos MeSH primário: Anormalidades Congênitas/economia
Planos de Assistência de Saúde para Empregados/economia
Gastos em Saúde/estatística & dados numéricos
Doenças do Prematuro/economia
[Mh] Termos MeSH secundário: Anormalidades Congênitas/terapia
Bases de Dados Factuais
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Doenças do Prematuro/terapia
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171112
[Lr] Data última revisão:
171112
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170922
[St] Status:MEDLINE


  8 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28880857
[Au] Autor:Kolor K; Chen Z; Grosse SD; Rodriguez JL; Green RF; Dotson WD; Bowen MS; Lynch JA; Khoury MJ
[Ad] Endereço:Office of Public Health Genomics, Division of Public Health Information Dissemination, Center for Surveillance, Epidemiology, and Laboratory Services, CDC, Atlanta, Georgia.
[Ti] Título:BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.
[So] Source:MMWR Surveill Summ;66(15):1-11, 2017 Sep 08.
[Is] ISSN:1545-8636
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PROBLEM/CONDITION: Genetic testing for breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) gene mutations can identify women at increased risk for breast and ovarian cancer. These testing results can be used to select preventive interventions and guide treatment. Differences between nonmetropolitan and metropolitan populations in rates of BRCA testing and receipt of preventive interventions after testing have not previously been examined. PERIOD COVERED: 2009-2014. DESCRIPTION OF SYSTEM: Medical claims data from Truven Health Analytics MarketScan Commercial Claims and Encounters databases were used to estimate rates of BRCA testing and receipt of preventive interventions after BRCA testing among women aged 18-64 years with employer-sponsored health insurance in metropolitan and nonmetropolitan areas of the United States, both nationally and regionally. RESULTS: From 2009 to 2014, BRCA testing rates per 100,000 women aged 18-64 years with employer-sponsored health insurance increased 2.3 times (102.7 to 237.8) in metropolitan areas and 3.0 times (64.8 to 191.3) in nonmetropolitan areas. The relative difference in BRCA testing rates between metropolitan and nonmetropolitan areas decreased from 37% in 2009 (102.7 versus 64.8) to 20% in 2014 (237.8 versus 191.3). The relative difference in BRCA testing rates between metropolitan and nonmetropolitan areas decreased more over time in younger women than in older women and decreased in all regions except the West. Receipt of preventive services 90 days after BRCA testing in metropolitan versus nonmetropolitan areas throughout the period varied by service: the percentage of women who received a mastectomy was similar, the percentage of women who received magnetic resonance imaging of the breast was lower in nonmetropolitan areas (as low as 5.8% in 2014 to as high as 8.2% in 2011) than metropolitan areas (as low as 7.3% in 2014 to as high as 10.3% in 2011), and the percentage of women who received mammography was lower in nonmetropolitan areas in earlier years but was similar in later years. INTERPRETATION: Possible explanations for the 47% decrease in the relative difference in BRCA testing rates over the study period include increased access to genetic services in nonmetropolitan areas and increased demand nationally as a result of publicity. The relative differences in metropolitan and nonmetropolitan BRCA testing rates were smaller among women at younger ages compared with older ages. PUBLIC HEALTH ACTION: Improved data sources and surveillance tools are needed to gather comprehensive data on BRCA testing in the United States, monitor adherence to evidence-based guidelines for BRCA testing, and assess receipt of preventive interventions for women with BRCA mutations. Programs can build on the recent decrease in geographic disparities in receipt of BRCA testing while simultaneously educating the public and health care providers about U.S. Preventive Services Task Force recommendations and other clinical guidelines for BRCA testing and counseling.
[Mh] Termos MeSH primário: Neoplasias da Mama/prevenção & controle
Genes BRCA1
Genes BRCA2
Testes Genéticos/estatística & dados numéricos
Planos de Assistência de Saúde para Empregados/estatística & dados numéricos
Neoplasias Ovarianas/prevenção & controle
Serviços Preventivos de Saúde/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Neoplasias da Mama/genética
Feminino
Disparidades em Assistência à Saúde
Seres Humanos
Meia-Idade
População Rural/estatística & dados numéricos
Estados Unidos
População Urbana/estatística & dados numéricos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170908
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.ss6615a1


  9 / 9468 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28880062
[Au] Autor:Collins SR; Gunja MZ; Doty MM
[Ad] Endereço:Commonwealth Fund
[Ti] Título:Following the ACA Repeal-and-Replace Effort, Where Does the U.S. Stand on Insurance Coverage? Findings from the Commonwealth Fund Affordable Care Act Tracking Survey, March--June 2017.
[So] Source:Issue Brief (Commonw Fund);2017:1-21, 2017 Sep.
[Is] ISSN:1558-6847
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Issue: After Congress's failure to repeal and replace the Affordable Care Act, some policy leaders are calling for bipartisan approaches to address weaknesses in the law's coverage expansions. To do this, policymakers will need data about trends in insurance coverage, reasons why people remain uninsured, and consumer perceptions of affordability. Goal: To examine U.S. trends in insurance coverage and the demographics of the remaining uninsured population, as well as affordability and satisfaction among adults with marketplace and Medicaid coverage. Methods: Analysis of the Commonwealth Fund Affordable Care Act Tracking Survey, March­June 2017 Findings and Conclusions: The uninsured rate among 19-to-64-year-old adults was 14 percent in 2017, or an estimated 27 million people, statistically unchanged from one year earlier. Uninsured rates ticked up significantly in three subgroups: 35-to-49-year-olds, adults with incomes of 400 percent of poverty or more (about $48,000 for an individual), and adults living in states that had not expanded Medicaid. Half of uninsured adults, or an estimated 13 million, are likely eligible for marketplace subsidies or the Medicaid expansion in their state. Four of 10 uninsured adults are unaware of the marketplaces. Adults in marketplace plans with incomes below 250 percent of poverty are much more likely to view their premiums as easy to afford compared with people with higher incomes. Policies to improve coverage include a federal commitment to supporting the marketplaces and the 2018 open enrollment period, expansion of Medicaid in 19 remaining states, and enhanced subsidies for people with incomes of 250 percent of poverty or more.
[Mh] Termos MeSH primário: Cobertura do Seguro/estatística & dados numéricos
Seguro Saúde/estatística & dados numéricos
Pessoas sem Cobertura de Seguro de Saúde/estatística & dados numéricos
Patient Protection and Affordable Care Act/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Afroamericanos
Grupo com Ancestrais do Continente Asiático
Comportamento do Consumidor
Custo Compartilhado de Seguro/estatística & dados numéricos
Dedutíveis e Cosseguros/estatística & dados numéricos
Definição da Elegibilidade
Grupo com Ancestrais do Continente Europeu
Planos de Assistência de Saúde para Empregados
Pesquisas sobre Serviços de Saúde
Trocas de Seguro de Saúde/estatística & dados numéricos
Hispano-Americanos
Seres Humanos
Imposto de Renda
Cobertura do Seguro/economia
Cobertura do Seguro/legislação & jurisprudência
Seguro Saúde/economia
Seguro Saúde/legislação & jurisprudência
Medicaid/estatística & dados numéricos
Meia-Idade
Pobreza
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:170908
[St] Status:MEDLINE


  10 / 9468 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28813219
[Au] Autor:Robinson JC; Whaley CM; Brown TT
[Ad] Endereço:From the School of Public Health, University of California at Berkeley, Berkeley (J.C.R., C.M.W., T.T.B.), and RAND, Santa Monica (C.M.W.) - both in California.
[Ti] Título:Association of Reference Pricing with Drug Selection and Spending.
[So] Source:N Engl J Med;377(7):658-665, 2017 08 17.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background In the United States, prices for therapeutically similar drugs vary widely, which has prompted efforts by public and private insurers to steer patients toward the lower-priced options. Under reference pricing, the insurer or employer establishes a maximum contribution it will make toward the price of a drug or procedure, and the patient pays the remainder. Methods We used difference-in-differences multivariable regression methods to analyze changes in prescriptions and pricing for 1302 drugs in 78 therapeutic classes in the United States, before and after implementation of reference pricing by an alliance of private employers. We assessed trends for the study group relative to those for an employee group that was not subject to reference pricing. The study included 1,122,741 prescriptions that were reimbursed during the period from 2010 through 2014. Results Implementation of reference pricing was associated with a higher percentage of prescriptions that were filled for the lowest-priced reference drug within its therapeutic class (difference in probability, 7.0 percentage points; 95% confidence interval [CI], 4.0 to 9.9), a lower average price paid per prescription (-13.9%; 95% CI, -23.8 to -2.7), and a higher rate of copayment by patients (5.2%; 95% CI, 0.2 to 10.4) than in the comparison group. During the first 18 months after implementation, spending for employers was $1.34 million lower and the amount of copayments for employees was $0.12 million higher than in the comparison group. Conclusions Implementation of reference pricing was associated with significant changes in drug selection and spending for a population of patients covered by employment-based insurance in the United States. (Funded by the Agency for Healthcare Research and Quality and the Genentech Foundation.).
[Mh] Termos MeSH primário: Custo Compartilhado de Seguro
Prescrições de Medicamentos/estatística & dados numéricos
Substituição de Medicamentos/tendências
Medicamentos sob Prescrição/economia
Honorários por Prescrição de Medicamentos
[Mh] Termos MeSH secundário: Prescrições de Medicamentos/economia
Substituição de Medicamentos/economia
Planos de Assistência de Saúde para Empregados/economia
Seres Humanos
Análise de Regressão
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Prescription Drugs)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170905
[Lr] Data última revisão:
170905
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170817
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMsa1700087



página 1 de 947 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde